Barrier. The barrier consists of a block of reinforced concrete not less than 3 m wide at the front and not less than 1.5 m high. The barrier shall be of such thickness that it weighs at least 70 tonnes. The front face shall be vertical, perpendicular to the axis of the run-up track, and covered with plywood boards 20 ± 1 mm thick in good condition. The barrier shall be either anchored in the ground or placed on the ground with, if necessary, additional arresting devices to limit its displacement. A barrier with different characteristics, but giving results at least equally conclusive, may likewise be used.
Barrier. The barrier shall consist of a block of reinforced concrete not less than 3 m wide in front and not less than 1.5 m high. The barrier shall be of such thickness that it weighs at least 70 metric tons. The front face shall be flat, vertical and perpendicular to the axis of the run-up track. It shall be covered with plywood boards 20 ± 2 mm thick, in good condition. A structure on a steel plate at least 25 mm thick may be placed between the plywood board and the barrier. A barrier with different characteristics may likewise be used, provided that the area of the impact surface is greater than the frontal crash area of the vehicle being tested and provided that it gives equivalent results.
Barrier. The front face of the barrier consists of a deformable structure as defined in Annex 9 of this Regulation. The front face of the deformable structure is perpendicular within ±1° to the direction of travel of the test vehicle. The barrier is secured to a mass of not less than 7 x 104 kg, the front face of which is vertical within ±1°. The mass is anchored in the ground or placed on the ground with, if necessary, additional arresting devices to restrict its movement.
Barrier. Revise to read as follows: (a)Barrier.
Barrier. Any surface that seals off the work area to inhibit the movement of fibers.
Barrier. Equipment preventing entry by an unauthorized person to a restricted area, structure or building, and providing physical protection against direct contact with Energized Parts under normal circumstances.
Barrier. 2.1.1 Barrier has already provided Abbott with sufficient Drug Substance for this programme.
2.1.0 Xxxrier, or its nominee, will perform milling and tabletting of the Bulk Product to produce Finished Product.
2.1.3 Barrier, or its nominee, will perform release and other testing in accordance with the Delimitation of Pharmaceutical Responsibilities Agreement set out in Schedule C to this Agreement.
Barrier. 2.1.1 Barrier has provided Abbott with material under the SCHEDULES B-1 and B-2 and Abbott will xxx xse up the remainder.
2.1.2 Barrier wilx xxxxorm milling and tabletting of the Bulk Product for technical assessment.
Barrier. 2.1.1 Barrier has provided Abbott with sufficient Drug Substance.
2.1.2 Barrier will provide Abbott with reference standards of the Drug Substance and related compounds necessary for the development and validation of the HPLC method.
2.1.3 Barrier will perform milling and tabletting of the Bulk Product for technical assessment. Barrier agrees to inform Abbott about all data obtained from the tested formulations for a joint evaluation of further steps.
Barrier. 2.1.1 Barrier will provide Abbott with [**] of GMP-quality Drug Substance (as Itraconazole) and [**] of GMP-quality HPMC free of charge together with a Certificate of Analysis and any information on drug handling, safety and relevant ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. toxicolgical data for Drug Substance (at least MSDS) which Abbott has not previously received.
2.1.2 Barrier will xxxxxxm the analytical testing necessary to release the Bulk Product for further processing.
2.1.3 Barrier will perform milling and tabletting of the Bulk Product to manufacture the Finished Product applicable for clinical trial supply.
2.1.4 Barrier will perform the final release of the clinical trial samples.
